01379nas a2200301   4500000000100000008004100001260001700042653001000059653001600069653001900085653003000104653001100134653001100145653001400156653001000170653002300180653001200203653000900215653003900224653001400263100001300277245009900290300001100389490000700400050003200407520062400439022001401063       2004                            d  c2004 Jul-Sep10aAdult10aClofazimine10aCohort Studies10aDrug Therapy, Combination10aFemale10aHumans10aIncidence10aIndia10aLeprostatic Agents10aleprosy10aMale10aPeripheral Nervous System Diseases10aPregnancy1 aJohn A S00aIncidence of neuritis among paucibacillary leprosy patients during treatment and surveillance.  a215-220 v76  aInfolep Library - available3 a<p>A cohort study was done on 180 patients receiving the standard WHO PB-MDT regimen at the TLM Hospital in Kolkata, during MDT and 2 years of surveillance to determine the incidence of neuritis. Neuritis occurred in only 2 out of the 180 patients, confirming that the current WHO treatment for PB-MDT is attendant with minimal risk of neuritis. No risk factors were found, except pregnancy in a female patient. While addition of clofazimine in the new U-MDT under trial might take care of the occasional neuritis, further clinical research might be useful to identify sub-groups of PB patients at risk of neuritis.</p>  a0254-9395